MBTPS1

Chr 16AR

membrane bound transcription factor peptidase, site 1

Also known as: CAOP, PCSK8, S1P, SEDKF, SKI-1

This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an initial autocatalytic processing event in the ER to generate a heterodimer which exits the ER and sorts to the cis/medial-Golgi where a second autocatalytic event takes place and the catalytic activity is acquired. It encodes a type 1 membrane bound protease which is ubiquitously expressed and regulates cholesterol or lipid homeostasis via cleavage of substrates at non-basic residues. Mutations in this gene may be associated with lysosomal dysfunction. [provided by RefSeq, Feb 2014]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismARLOEUF 0.592 OMIM phenotypes
Clinical SummaryMBTPS1
🧬
Gene-Disease Validity (ClinGen)
spondyloepiphyseal dysplasia, kondo-fu type · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
31 unique Pathogenic / Likely Pathogenic· 267 VUS of 616 total submissions
📖
GeneReview available — MBTPS1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.59LOEUF
pLI 0.000
Z-score 4.08
OE 0.42 (0.300.59)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
-1.45Z-score
OE missense 1.16 (1.091.24)
715 obs / 613.8 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.42 (0.300.59)
00.351.4
Missense OE?1.16 (1.091.24)
00.61.4
Synonymous OE?1.20
01.21.6
LoF obs/exp: 24 / 57.4Missense obs/exp: 715 / 613.8Syn Z: -2.42

This gene — mechanism propensity

DN
0.6453th %ile
GOF
0.4678th %ile
LOF
0.4136th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
LOF65% of P/LP variants are LoF

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

616 submitted variants in ClinVar

Classification Summary

Pathogenic23
Likely Pathogenic8
VUS267
Likely Benign236
Benign35
Conflicting7
23
Pathogenic
8
Likely Pathogenic
267
VUS
236
Likely Benign
35
Benign
7
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
15
2
6
0
23
Likely Pathogenic
5
3
0
0
8
VUS
0
256
9
2
267
Likely Benign
0
11
102
123
236
Benign
0
2
21
12
35
Conflicting
7
Total20274138137576

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

45 pathogenic / likely-pathogenic (of 80) ClinVar copy-number / structural variants overlap MBTPS1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

MBTPS1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →